FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Somaxon CEO resigns

Somaxon CEO Kenneth M. Cohen has announced this resignation, effective December 31, 2007. The company's non-executive board chairman David F. Hale will serve as interim CEO until a permanent replacement for Cohen is hired. Specific reasons for Cohen's resignation were not outlined in the announcement, though the company noted that "management changes are part of a transition plan." Somaxon is based in San Diego, CA and is developing psychiatry and neurology treatments.

- see Somaxon's release

Related Articles:
Somaxon touts latest Phase III results for Silenor. Report
Somaxon reveals mid-stage data on smoking cessation. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Phase III   Somaxon   Biotech CEO   smoking cessation